Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NNC0471-0119 B
- Development stage
- Unknown
- Lead developer
- Novo Nordisk
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
NNC0471-0119 B is one of three formulations of NNC0471-0119, a new rapid-acting insulin analogue developed by Novo Nordisk A/S for the treatment of type 1 diabetes. It is designed for administration via an insulin pump as a bolus dose on top of a continuous basal rate. The drug is currently being investigated for its pharmacokinetic, pharmacodynamic, safety, and tolerability properties.
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on NNC0471-0119 B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NNC0471-0119 B.